Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Moderna, Inc. - Common Stock
(NQ:
MRNA
)
47.44
-4.15 (-8.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
Via
Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
June 03, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Moderna to Present at Upcoming Conference in June 2026
June 02, 2026
Via
ACCESS Newswire
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
From
BioMedWire
Via
GlobeNewswire
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
June 01, 2026
Via
ACCESS Newswire
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
June 01, 2026
Via
ACCESS Newswire
Moderna Recognized by TIME as One of the World's Most Impactful Companies
May 12, 2026
Via
ACCESS Newswire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates
May 11, 2026
Via
Investor Brand Network
Topics
Intellectual Property
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026
From
BioMedWire
Via
GlobeNewswire
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
May 06, 2026
Via
ACCESS Newswire
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
May 01, 2026
Via
ACCESS Newswire
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
April 21, 2026
Via
ACCESS Newswire
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
April 21, 2026
Via
ACCESS Newswire
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
April 21, 2026
Via
ACCESS Newswire
Moderna to Present at Upcoming Conferences in May 2026
April 21, 2026
Via
ACCESS Newswire
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
April 17, 2026
Via
ACCESS Newswire
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
April 15, 2026
Via
ACCESS Newswire
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
April 06, 2026
Via
ACCESS Newswire
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
March 03, 2026
Via
ACCESS Newswire
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
February 27, 2026
Via
ACCESS Newswire
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
February 23, 2026
From
Tectonic Therapeutic
Via
GlobeNewswire
Moderna to Present at Upcoming Conferences in March 2026
February 19, 2026
Via
ACCESS Newswire
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
February 18, 2026
Via
ACCESS Newswire
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
February 17, 2026
Via
ACCESS Newswire
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
February 13, 2026
Via
ACCESS Newswire
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
February 10, 2026
Via
ACCESS Newswire
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
February 10, 2026
Via
ACCESS Newswire
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
February 05, 2026
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
February 04, 2026
From
Defiance ETFs
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
